MX2017009449A - Inhibidor jak. - Google Patents

Inhibidor jak.

Info

Publication number
MX2017009449A
MX2017009449A MX2017009449A MX2017009449A MX2017009449A MX 2017009449 A MX2017009449 A MX 2017009449A MX 2017009449 A MX2017009449 A MX 2017009449A MX 2017009449 A MX2017009449 A MX 2017009449A MX 2017009449 A MX2017009449 A MX 2017009449A
Authority
MX
Mexico
Prior art keywords
jak inhibitor
jak
disclosed
compounds
series
Prior art date
Application number
MX2017009449A
Other languages
English (en)
Inventor
Hao Wu
Wang Fei
Z Ding Charles
Chen Shuhui
Hu Guoping
Mao Weiwei
Fan Lili
Li Jian
Original Assignee
Wuxy Fortune Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxy Fortune Pharmaceutical Co Ltd filed Critical Wuxy Fortune Pharmaceutical Co Ltd
Publication of MX2017009449A publication Critical patent/MX2017009449A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención describe una serie de inhibidores JAK, y describe particularmente un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo y el uso del mismo en la preparación de fármacos para tratar enfermedades relacionadas con JAK.
MX2017009449A 2015-01-20 2016-01-19 Inhibidor jak. MX2017009449A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510029259 2015-01-20
CN201610016564 2016-01-11
PCT/CN2016/071313 WO2016116025A1 (zh) 2015-01-20 2016-01-19 Jak抑制剂

Publications (1)

Publication Number Publication Date
MX2017009449A true MX2017009449A (es) 2018-05-28

Family

ID=56416433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009449A MX2017009449A (es) 2015-01-20 2016-01-19 Inhibidor jak.

Country Status (15)

Country Link
US (1) US10617690B2 (es)
EP (1) EP3248980B1 (es)
JP (1) JP6742323B2 (es)
KR (1) KR101864561B1 (es)
CN (1) CN108349977B (es)
AU (1) AU2016208906B2 (es)
CA (1) CA2979425C (es)
EA (1) EA036122B1 (es)
ES (1) ES2962330T3 (es)
HU (1) HUE064003T2 (es)
MX (1) MX2017009449A (es)
PL (1) PL3248980T3 (es)
TW (1) TWI690531B (es)
UA (1) UA118149C2 (es)
WO (1) WO2016116025A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6937828B2 (ja) * 2016-11-23 2021-09-22 江蘇恒瑞医薬股▲ふん▼有限公司 ピロロ6員複素芳香環誘導体の製造方法、および中間体
CN107778321A (zh) * 2017-10-31 2018-03-09 无锡福祈制药有限公司 一种托法替尼类似物
CN107602590A (zh) * 2017-10-31 2018-01-19 无锡福祈制药有限公司 具有Janus激酶抑制活性的桥环化合物
CN107573364A (zh) * 2017-10-31 2018-01-12 无锡福祈制药有限公司 一种jak激酶抑制剂
CN107602591A (zh) * 2017-10-31 2018-01-19 无锡福祈制药有限公司 一种Janus激酶3抑制剂
CN107652308A (zh) * 2017-10-31 2018-02-02 无锡福祈制药有限公司 一种Janus激酶3抑制剂
CN107805259A (zh) * 2017-10-31 2018-03-16 无锡福祈制药有限公司 一种吡咯并嘧啶类化合物
JP7462951B2 (ja) * 2018-03-21 2024-04-08 リャオ,シビン Jak阻害剤
WO2020156271A1 (zh) 2019-02-02 2020-08-06 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
CN111518096B (zh) * 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020198583A1 (en) * 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Bicyclic jak inhibitors and uses thereof
KR20220017995A (ko) * 2019-06-05 2022-02-14 광조우 조요 파마테크 컴퍼니 리미티드 피롤로피리미딘 화합물 및 그 용도
CN112480116B (zh) * 2019-09-11 2024-03-29 南京正大天晴制药有限公司 Pkb抑制剂
CN110483514B (zh) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
CN110724142B (zh) * 2019-10-29 2022-09-02 启元生物(杭州)有限公司 一种作为jak激酶抑制剂的酰胺或磺酰胺取代的肼衍生物
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112168827A (zh) * 2020-11-03 2021-01-05 卓和药业集团有限公司 一种用于治疗银屑病的药物组合物及其制备方法
CN115124526B (zh) * 2020-12-04 2024-01-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物中间体及其制备方法
CN113372366B (zh) * 2020-12-04 2022-08-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的盐、其晶型及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ATE423120T1 (de) * 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
WO2002057267A1 (en) * 2000-12-01 2002-07-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
EP1485100B1 (en) * 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azinylaminoazoles as inhibitors of protein kinases
JP2006501200A (ja) * 2002-07-23 2006-01-12 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
KR100846988B1 (ko) * 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
WO2008029237A2 (en) * 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
WO2008144253A1 (en) * 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
RU2493157C2 (ru) * 2008-08-20 2013-09-20 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА
NZ603446A (en) 2010-04-14 2014-05-30 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
WO2013055645A1 (en) 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
WO2014003483A1 (en) * 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
US8551542B1 (en) 2012-09-20 2013-10-08 Basic Research L.L.C. Methods and compositions for increasing growth hormones
SI3539965T1 (sl) 2013-12-09 2021-07-30 Unichem Laboratories Limited Izboljšan postopek za pripravo (3R,4R)-(1-benzil-4-metilpiperidin-3-il)-metilamina

Also Published As

Publication number Publication date
JP2018502899A (ja) 2018-02-01
US20170360794A1 (en) 2017-12-21
US10617690B2 (en) 2020-04-14
ES2962330T3 (es) 2024-03-18
EP3248980A4 (en) 2018-08-01
WO2016116025A1 (zh) 2016-07-28
PL3248980T3 (pl) 2024-03-04
EP3248980C0 (en) 2023-09-06
HUE064003T2 (hu) 2024-02-28
AU2016208906A1 (en) 2017-08-31
CN108349977B (zh) 2021-05-25
CN108349977A (zh) 2018-07-31
UA118149C2 (uk) 2018-11-26
JP6742323B2 (ja) 2020-08-19
TWI690531B (zh) 2020-04-11
KR101864561B1 (ko) 2018-06-04
CA2979425C (en) 2020-04-14
EP3248980B1 (en) 2023-09-06
TW201627309A (zh) 2016-08-01
AU2016208906B2 (en) 2018-07-12
CA2979425A1 (en) 2016-07-28
EA036122B1 (ru) 2020-09-30
KR20170101309A (ko) 2017-09-05
EA201791576A1 (ru) 2018-03-30
EP3248980A1 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
MX2017009449A (es) Inhibidor jak.
MX2017013797A (es) Inhibidor de janus quinasa.
MX2022011029A (es) Compuestos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
PH12016501750A1 (en) Human plasma kallikrein inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2016008688A (es) Compuestos terapéuticos inhibidores.
TW201613872A (en) IRAK4 inhibiting agents
UA111382C2 (uk) Інгібітори протеїнкінази
AU2014267235A8 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
MX2017013798A (es) Inhibidores jak.
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
PH12016501462A1 (en) Neprilysin inhibitors
MX2017007607A (es) Inhibidores de necrosis celular y metodos relacionados.
MX2017008386A (es) Administración específica del sitio de un inhibidor de btk.
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MY193239A (en) Novel b-lactamase inhibitors
EA201692332A1 (ru) Борсодержащие ингибиторы протеасом для применения после первичной противораковой терапии
AU2016248387A8 (en) Preparation and use of kinase inhibitor
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.